Richard Hengel, MD
Infectious Disease · Atlanta, GANPI 1972605665
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,480 of the $6,808 with a category attached, or 65.8%. 23 manufacturers reported payments, led by Ferring Pharmaceuticals Inc. at 38.3% of the total. Reporting peaked in 2023 at $2,713 and has fallen 85.4% since, to $397 in 2025.
Across 108 payments — averaging $63.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ferring Pharmaceuticals Inc.$3K
- Merck$2K
- Viiv Healthcare Company$388
- Gilead$328
- Paratek Pharmaceuticals, Inc.$293
- AbbVie$264
- plus $681 from 17 others
Across 41 payments — averaging $4409.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$165K
- Janssen Research & Development, LLC$16K
What the payments were for
- Consulting fees$4,48066%
- Food & beverage$2,29634%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ferring Pharmaceuticals Inc. | 3 | $2,607 |
| Merck | 20 | $2,248 |
| Viiv Healthcare Company | 16 | $388 |
| Gilead | 16 | $328 |
| Paratek Pharmaceuticals, Inc. | 4 | $293 |
| AbbVie(2 entities) | 17 | $264 |
| Insmed, Inc. | 5 | $115 |
| Theratechnologies Inc. | 5 | $111 |
| Melinta Therapeutics, LLC | 4 | $74 |
| Octapharma USA, Inc. | 1 | $50 |
| Aimmune Therapeutics, Inc. | 2 | $49 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $40 |
| Janssen Scientific Affairs, LLC | 2 | $32 |
| Cumberland Pharmaceuticals, Inc. | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $24 |
| AstraZeneca | 1 | $22 |
| La Jolla Pharmaceutical Company | 1 | $21 |
| Pfizer | 1 | $21 |
| Shionogi Inc | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $19 |
| Johnson & Johnson | 1 | $15 |
| Hydrofera LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,808 in reported general payments places this provider in the 80th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 88 | $410,788 |
| TivicayDolutegravir Sodium | 56 | $196,295 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 15 | $105,062 |
| DescovyEmtricitabine/Tenofov Alafenam | 33 | $77,072 |
| JulucaDolutegravir/Rilpivirine | 14 | $62,751 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 12 | $45,204 |
| PrezcobixDarunavir/Cobicistat | 17 | $43,026 |
| Maraviroc | 13 | $34,384 |
| IsentressRaltegravir Potassium | 16 | $31,529 |
| PifeltroDoravirine | 17 | $30,077 |
| Etravirine | 13 | $15,057 |
| Darunavir | 20 | $11,509 |
| Emtricitabine | 11 | $4,283 |
| Ampicillin Sodium | 12 | $3,885 |
| CeftriaxoneCeftriaxone Sodium | 14 | $492 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $328 | $592,923136 claims |
| Viiv Healthcare CompanyTivicay, Juluca, Triumeq | $388 | $304,25082 claims |
| MerckIsentress, Pifeltro | $2,248 | $61,60633 claims |
| Johnson & JohnsonPrezcobix | $15 | $43,02617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 260 infectious disease providers in Georgia.
Other infectious disease in Atlanta
- Zandraetta Tims-CookAtlanta$848K
- Larry AndersonAtlanta$300K
- Quintin RobinsonAtlanta$270K
- James McMillenAtlanta$177K
- Leandro MenaAtlanta$141K
- Colleen KraftAtlanta$103K
- Walter OrensteinAtlanta$78K
- Nadine RouphaelAtlanta$66K
- Kimberly WorkowskiAtlanta$53K
- Bernard BransonAtlanta$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.